NASDAQ: GHGuardant Health Inc Stock
$25.36-0.88 (-3.35%)
Updated May 17, 2024
GH Price
$25.36
Fair Value Price
N/A
Market Cap
$3.10B
52 Week Low
$15.81
52 Week High
$41.06
P/E
-6.4x
P/B
45.45x
P/S
4.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$603.73M
Earnings
-$460.90M
Gross Margin
60.4%
Operating Margin
-75.77%
Profit Margin
-76.3%
Debt to Equity
23.96
Operating Cash Flow
-$281M
Beta
1.34
Next Earnings
May 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A
GH Overview
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GH is poor value based on its book value relative to its share price (45.45x), compared to the US Diagnostics & Research industry average (4.47x)
P/B vs Industry Valuation
GH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GH due diligence checks available for Premium users.
Be the first to know about important GH news, forecast changes, insider trades & much more!
GH News
Valuation
GH fair value
Fair Value of GH stock based on Discounted Cash Flow (DCF)
Price
$25.36
Fair Value
$20.59
Overvalued by
23.16%
GH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.4x
Industry
38.96x
Market
30.97x
GH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
45.45x
Industry
4.47x
GH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GH's financial health
Profit margin
Revenue
$168.5M
Net Income
-$115.0M
Profit Margin
-68.2%
GH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.7B
Liabilities
$1.6B
Debt to equity
23.96
GH's short-term assets ($1.31B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GH's long-term liabilities ($1.42B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$30.3M
Investing
$28.1M
Financing
-$1.1M
GH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GH vs Diagnostic & Research Stocks
Guardant Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.